Departments of Pediatric Ophthalmology, Strabismus and Neuro-Ophthalmology, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India.
Cornea and Anterior Segment, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India.
Indian J Ophthalmol. 2022 Dec;70(12):4400-4404. doi: 10.4103/ijo.IJO_679_22.
Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy remains uncertain among high myopic children. This study aimed to evaluate the efficacy and safety of low-concentration atropine eye drop (0.01%) in high myopic children.
A non-randomized, parallel-group, longitudinal interventional cohort study. Myopic children were divided into two groups: (1) the intervention arm of children who received one drop of topical 0.01% atropine once a day at bedtime and (2) the control arm, in which enrolled children who were on observation only. Repeated measurements of spherical equivalent refractive errors (SERs) were performed at baseline and 1 and 2 years after treatment.
A total of 37 eyes were enrolled in the intervention arm (allocated to 0.01% atropine at year 1 follow-up) and 23 eyes in the control arm. After 1 year of 0.01% atropine therapy, the myopia progression was 0.15 ± 0.9 D in the intervention group versus 1.1 ± 1 D in the control group (P = 0.001). Similarly, after 2 years of treatment, the myopia progression was 0.3 ± 1.1 D in the intervention group versus 1.4 ± 1.1 D in the control group (P ≤ 0.001).
Compared to no treatment, 0.01% atropine treatment had shown better effect on myopia progression in high myopic children.
低浓度阿托品是一种治疗近视进展的新兴疗法，但在高度近视儿童中的疗效仍不确定。本研究旨在评估低浓度阿托品滴眼液（0.01%）治疗高度近视儿童的疗效和安全性。
一项非随机、平行组、纵向干预性队列研究。将近视儿童分为两组：（1）干预组，每晚接受一滴 0.01%阿托品眼药水治疗；（2）对照组，仅进行观察。在基线和治疗 1 年和 2 年后，分别对等效球镜（SER）进行重复测量。
共有 37 只眼被纳入干预组（全部在第 1 年随访时分配至 0.01%阿托品组），23 只眼被纳入对照组。在 0.01%阿托品治疗 1 年后，干预组的近视进展为 0.15 ± 0.9 D，而对照组为 1.1 ± 1 D（P = 0.001）。同样，治疗 2 年后，干预组的近视进展为 0.3 ± 1.1 D，而对照组为 1.4 ± 1.1 D（P ≤ 0.001）。
与不治疗相比，0.01%阿托品治疗对高度近视儿童的近视进展有更好的效果。
